Thanks to Greg Stephens for sharing this blog and the article written by Jessica Wapner. You will notice that she has written a book (at last someone has understood this fantastic story) called The Philadelphia Chromosome due out in May.......... I for one am looking forward to reading this it as this story has become such a big part of my life.
For those who have a few spare hours/days this June and live within flying/driving distance of Portland Oregon, you might like to turn up at
the following event at Powells Books (a wonderful book shop that is a very significant place for me as I spent quite a few hours in there when I lived in Portland between August and October 1999, inorder to participate in the phase ll trial for STI571 - imatinib/Glivec). I would love to be there.
On June 11, 2013 at 7.30 - 9.00pm,
Jessica Wapner will be joined by Dr. Brian Druker, who is features prominently in 'The Philadelphia Chromosome'
at
Powell’s Books,
1005 W Burnside,
Portland, OR,
97209, US.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------
Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
By Jessica Wapner
Posted: February 6, 2013: Work In Progress
"How did a rare disease like CML, which strikes about 5,400 people in the U.S. annually, come to have three generations of highly successful treatments? That is a story for another time. (Well, shameless plug, it’s the story told in my forthcoming book, The Philadelphia Chromosome, out this May.) However, the story of ponatinib stands on its own because it is yet another targeted drug that is offering a treatment to patients who would otherwise have died from their disease by now, having run through all other options.
Recently I spoke with Michael Mauro, of Oregon Health & Sciences University (OHSU), who was a lead investigator both on the early lab studies of ponatinib and on the clinical trials that led to its approval. Here’s what he had to say about this new drug and why it matters."
Read full post here:
http://blogs.plos.org/workinprogress/